Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...